Weleader Biomedical Co (ROCO:7713) Other Stockholders Equity: NT$111 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7713 Weleader Biomedical Co Ltd ROCO:7713
69 GF Score
Price NT$75.00
GF Value NT$74.27
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Weleader Biomedical Co Other Stockholders Equity?

Weleader Biomedical Co ROCO:7713 +1.49% 69 Other Stockholders Equity is NT$111 Mil as of Jun. 2026. GuruFocus rates ROCO:7713 with a GF Score™ of 69/100 and a GF Value™ of NT$74.27 (Fairly Valued). The stock has 6 warning signs investors should review.

Weleader Biomedical Co's Other Stockholders Equity for the quarter that ended in Jun. 2026 was NT$111 Mil.

Weleader Biomedical Co's quarterly Other Stockholders Equity stayed the same from Dec. 2025 (NT$95 Mil) to Mar. 2026 (NT$95 Mil) but then increased from Mar. 2026 (NT$95 Mil) to Jun. 2026 (NT$111 Mil).

Weleader Biomedical Co's annual Other Stockholders Equity increased from Dec. 2023 (NT$60 Mil) to Dec. 2024 (NT$64 Mil) and increased from Dec. 2024 (NT$64 Mil) to Dec. 2025 (NT$95 Mil).

Weleader Biomedical Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Weleader Biomedical Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Weleader Biomedical Co Other Stockholders Equity Chart

Weleader Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 22.22 29.79 60.46 63.80 94.92

Weleader Biomedical Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.82 80.82 94.92 94.92 110.85
ROCO:7713
69GF Score
Weleader Biomedical Co Ltd ROCO:7713
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Weleader Biomedical Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$111 Mil mean?
Weleader Biomedical Co (ROCO:7713) has a Other Stockholders Equity of NT$111 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Weleader Biomedical Co and its competitors.
Is Weleader Biomedical Co's Other Stockholders Equity too high?
Weleader Biomedical Co's current Other Stockholders Equity is NT$111 Mil. Overall, Weleader Biomedical Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Other Stockholders Equity compare to ABT and SYK?
Weleader Biomedical Co's Other Stockholders Equity of NT$111 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current Other Stockholders Equity is NT$111 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Weleader Biomedical Co (ROCO:7713) is currently considered Fairly Valued. The stock's GF Value™ is NT$74.27, compared to a current price of NT$75.00 — trading 1% above its estimated fair value. The current Other Stockholders Equity is NT$111 Mil. Weleader Biomedical Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Other Stockholders Equity is NT$111 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Weleader Biomedical Co (ROCO:7713) Overvalued in 2026?

Based on GuruFocus' analysis, Weleader Biomedical Co stock appears to be overvalued. The current stock price of NT$75.00 is trading 1% above its estimated GF Value™ of NT$74.27. GuruFocus considers Weleader Biomedical Co to be Fairly Valued.

Key valuation signals for ROCO:7713:

  • Other Stockholders Equity: NT$111 Mil
  • GF Value™: NT$74.27 vs. price of NT$75.00 (1% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the ROCO:7713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Weleader Biomedical Co Business Description

Address No. 80, Minzu 1st Road, 19th Floor - 1 & 2, Sanmin District, Kaohsiung, TWN
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
69GF Score

Get the complete analysis for ROCO:7713

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$75.00
Price
NT$74.27
GF Value